D-0649-2017 Class III Terminated

Recalled by Dr. Reddy's Laboratories, Inc. — Princeton, NJ

FDA drug recall D-0649-2017 was initiated by Dr. Reddy's Laboratories, Inc. on Mar 6, 2017 and is designated Class III. Reason for recall: Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine. The recall status is terminated (terminated Dec 21, 2017). Affected quantity: 1,728 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 12, 2017
Initiation Date
Mar 6, 2017
Termination Date
Dec 21, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,728 bottles

Product description

RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60

Reason for recall

Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.

Distribution pattern

U.S. nationwide

Code information

Lot #C607323, Exp 10/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0649-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0649-2017. Report a data issue: hello@regdatalab.com.